Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to address disease-causing proteins that have historically been highly challenging to target.
Arvinas is a leader within the TPD field with its revolutionary PROTAC® (PROteolysis-Targeted Chimera) protein degrader platform which harnesses the body’s natural protein disposal system to eliminate disease-causing proteins.
Clinical trials are underway in researching Arvinas’ PROTAC® protein degrader technology that could potentially play a role in the treatment of certain cancers. Research is also ongoing in the preclinical setting, including neurodegenerative diseases.
This webinar brings together a community of experts who will present recent research and perspectives in the exciting, fast-moving field of TPD.
Dr. Angela Cacace serves as Senior Vice President of Neuroscience and Platform Biology at Arvinas. Dr. Cacace brings more than two decades of biopharmaceutical research and pharmacology experience, contributing to four marketed drugs and over 18 development candidates. Previously, Dr. Cacace served as the Vice President of Biology at Fulcrum Therapeutics, where she built the biology platform and delivered the first development candidate for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
Additionally, Dr. Cacace was the Director of Neuroscience and Genetically Defined Diseases at Bristol Myers Squibb, where she spearheaded alternative therapeutic modalities and was a co-inventor on several development candidates. Throughout her time at Bristol Myers Squibb, she was responsible for building research-wide teams and initiatives, including the Lead Profiling Function, GPCR High Throughput Screening Team and the Cellular Resource Team. While serving as a Senior Principal Scientist in Cancer Biology at Pfizer, together with her team, she discovered a novel anti-angiogenic antibody development candidate.
Dr. Cacace received her B.S. in Biology from Fairfield University, Ph.D. in Pharmacology from Columbia University and completed her postdoctoral research in Oncology at Bristol Myers Squibb and the National Cancer Institute.
Danette Daniels, Ph.D., joined Foghorn Therapeutics in February 2022 as VP of the Protein Degrader Platform. She brings more than 20 years of cancer research experience in focused areas of chromatin, small molecules, and targeted protein degradation.
Prior to joining Foghorn, Danette was a R&D group leader of functional proteomics at Promega Corporation. There she led teams involved in both technology innovation and basic science research, managing collaborations with academic, biotech, and pharma laboratories. She was an early leader in the field of targeted protein degradation, pioneering approaches to monitor cellular kinetics and mechanisms of degradation, co-developed a new PROTAC modality, and since joining Foghorn leads development of therapeutic degraders. Her contributions have significantly impacted the broader research community by advancing discovery and enabling understanding of this new class of therapeutics. In 2023 she initiated a global Women in TPD & Induced Proximity group dedicated to recognizing female achievements in this emerging field and the group has rapidly grown to 600 members.
Danette received her B.A. from Columbia University and a Ph.D. in biophysics from Yale University under the direction of Axel Brunger. She completed a postdoctoral fellowship at Stanford University, funded by the American Cancer Society, with Bill Weis and Roel Nusse. She has published more than 50 scientific peer-reviewed articles and is a thought leader in the space and a frequent presenter at seminars, most notably at the New York Academy of Science, NIH/NIAID, AACR, and Dana Farber Cancer Institute. In 2022 she was elected to be a member of the AACR Chemistry in Cancer Research working group.
Ian Taylor, PhD, serves as the Chief Scientific Officer at Arvinas. Prior to joining Arvinas, Dr. Taylor served a decade at Pfizer Oncology as an Early Development Team Leader. During this time, Dr. Taylor was responsible for leading a cross-functional drug development team that conducted Phase 1 and Phase 2 clinical trials for multiple assets in several cancer indications. He also served as Senior Director of Translational Oncology, where he was responsible for directing translational science activities, which included designing and executing translational research plans and leading companion diagnostic partnerships for programs in both preclinical and clinical (Phase 1 -3) stages.
Dr. Taylor also worked at Bayer Healthcare Pharmaceuticals, holding positions of increasing responsibility, including Vice President of Cancer Biology, where he led biology aspects of small molecule drug discovery of cancer therapeutics in the mechanistic areas of signal transduction, cell cycle regulation, angiogenesis and apoptosis.
During his tenure, the Cancer Biology group delivered numerous molecules to the Development organization. He also started and led the Biomarker group, which contributed to the development of sorafenib.
Dr. Taylor earned his B.A. from Bowdoin College and his Ph.D. in Molecular Biology and Genetics from Harvard University. He also completed his postdoctoral training in the laboratory of Dr. Harold Varmus at the University of California, San Francisco and the National Institutes of Health (NIH).
Matthew Disney, Ph.D., is the chair of UF Scripps Biomedical Research’s Department of Chemistry. He received his Ph.D. from the University of Rochester in 2003. Dr. Disney’s research group, the Disney Lab, develops rational approaches to design selective therapeutics from only genome sequences.
As head of the client success team at Endpoints News, Kari oversees campaign delivery and strategy for all advertising and client-directed webinars. She brings nearly 20 years of diverse experience across strategic communications, content development and operational leadership.